Clinical Trials

Inclusion Criteria:

1. Appropriately enrolled in the BASECAMP-1 A2 Biotherapeutics, Inc. study, with tissue
demonstrating LOH of HLA-A*02 by NGS (whenever possible from the primary site),
successful apheresis and PBMC processing, and with sufficient stored cells available
for Tmod CAR T-cell therapy.

2. Histologically confirmed recurrent unresectable, locally advanced, or metastatic CRC,
NSCLC, PANC, OVCA, MESO, or other solid tumors with MSLN expression. Measurable
disease is required with lesions of >1.0 cm by CT.

3. Received previous required therapy for the appropriate solid tumor disease as
described in the protocol.

4. Has adequate organ function as described in the protocol.

5. ECOG performance status of 0 to 1.

6. Life expectancy of ≥ 3 months.

7. Willing to comply with study schedule of assessments including long term safety follow
up.

Exclusion Criteria:

1. Has disease that is suitable for local therapy or able to receive standard of care
therapy that is therapeutic and not palliative.

2. Prior allogeneic stem cell transplant.

3. Prior solid organ transplant.

4. MESO with pleural involvement extending into the peritoneum.

5. Cancer therapy within 3 weeks or 3 half lives of A2B694 infusion.

6. Radiotherapy within 28 days of A2B694 infusion.

7. Unstable angina, arrhythmia, myocardial infarction, or any other significant cardiac
disease within the last 6 months.

8. Any new symptomatic pulmonary embolism (PE) or a deep vein thrombosis (DVT) within 3
months of enrollment. Therapeutic dosing of anticoagulants is allowed for history of
PE or DVT if greater than 3 months from time of enrollment, and adequately treated.

9. History of interstitial lung disease including drug-induced interstitial lung disease
and radiation pneumonitis that requires treatment with prolonged steroids or other
immune suppressive agents within 1 year.

10. Requires supplemental home oxygen.

11. Females of childbearing potential who are pregnant or breastfeeding.

12. Subjects, both male and female, of childbearing potential who are not willing to
practice birth control from the time of consent through 6 months post infusion of
A2B694.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/24/23. Questions regarding updates should be directed to the study team contact.